Pitoxil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pitoxil

Quick Facts

Property Description
Active ingredient Moxifloxacin
Form Tablets, Intravenous Solution, Ophthalmic Solution
Pharmacological class Fluoroquinolone Antibiotic
Common use Systemic and local bacterial infections
Origin Synthetic

What Type of Antibacterial Medicine is Pitoxil?

Pitoxil is a pharmaceutical product containing the single active ingredient, Moxifloxacin, which is a powerful, chemically synthetic substance classified as a fluoroquinolone antibiotic. This medication belongs to the quinolone antibacterial drug class, a group reserved for treating infections caused by susceptible bacterial pathogens. Moxifloxacin is distinguished as a fourth-generation fluoroquinolone by its unique chemical structure, which grants it enhanced activity against pathogens commonly associated with respiratory infections, a characteristic clinically recognized in pharmacological studies.

The drug utilizes the dual-inhibitory action of Moxifloxacin to achieve a bactericidal effect. This mechanism involves the medicine actively killing target bacteria by blocking two essential bacterial enzymes, DNA gyrase and topoisomerase IV.

Forms and Delivery: Pitoxil’s Available Preparations

Pitoxil is manufactured in various physical forms to accommodate different clinical requirements and routes of administration. These preparations include film-coated tablets for oral ingestion, a sterile intravenous solution for injection directly into the bloodstream, and an ophthalmic solution formulated as eye drops. This variety ensures that the active agent, Moxifloxacin, can be reliably delivered either systemically throughout the body for widespread infections or locally to a specific site, such as the surface of the eye. All forms contain the same core active compound and are available only by prescription.

General Purpose: Why is Pitoxil Prescribed?

The general therapeutic purpose of Pitoxil is to clear the body of severe or persistent bacterial infections. By specifically disrupting the essential DNA processes that bacteria rely on for survival and replication, the medication rapidly eradicates the disease-causing pathogens. A typical scenario involves its use when treating bacterial infections that require a broad-spectrum approach, particularly in cases where the pathogen is resistant to older classes of antibiotics.

Regulatory References

  1. NIH, National Library of Medicine

What side effects are possible with Pitoxil?

Possible side effects and safety information

The official safety profile for Pitoxil (Moxifloxacin) highlights specific categories of adverse reactions as documented in regulatory sources such as the FDA and EMA. Reactions are classified by frequency and grouped into System-Organ Classes (SOC) based on the affected physiological system.

Classification Category Examples from Official Documentation
Common Effects Nausea, Diarrhea, Headache, and Dizziness are frequently reported adverse reactions based on clinical trial data.
SOC Groupings Documented effects involve the Musculoskeletal, Nervous System, Cardiac, and Hepatobiliary systems.

Serious adverse reactions are a defining element of the safety profile. The medicine is officially associated with disabling and potentially irreversible reactions, including Tendinitis and Tendon Rupture, Peripheral Neuropathy (affecting sensation and motor function), and serious Central Nervous System effects such as seizures and psychoses. Other serious risks include Fulminant Hepatitis potentially leading to liver failure, and severe cutaneous reactions like Stevens-Johnson syndrome. These reactions may occur during therapy or even months after treatment completion.

Specific population-based safety statements are included in the labeling. Older adults face a documented increased risk for tendon disorders. The medicine is contraindicated in patients with a history of Myasthenia Gravis due to the potential for muscle weakness exacerbation, and in individuals with pre-existing cardiac conditions or severe hepatic impairment. Furthermore, the drug is formally restricted to patients who lack alternative treatment options for certain milder infections, reflecting the significance of the documented serious risks.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Pitoxil overdose identifies a risk of exaggerated clinical manifestations. Documented overdose presentations may include general symptoms such as vomiting, dizziness, and agitation. The most critical regulatory concern involves the cardiovascular system, where overdose may cause dose-related prolongation of the QT interval on the electrocardiogram (ECG), carrying a documented risk of severe ventricular arrhythmias. Effects on the Central Nervous System (CNS), including seizures, are also noted.

The regulatory guidance on managing overdose mandates that patients seek immediate medical attention and get medical help right away. The patient should be placed under continuous ECG monitoring and carefully observed in a clinical setting. Management is strictly symptomatic and supportive, as no specific antidote is known for Pitoxil overdose. For oral overdose, official instructions include administering activated charcoal immediately to minimize systemic drug absorption. Elderly patients and those with existing renal or hepatic impairment are identified as populations potentially facing an increased risk of severe outcomes.

Therapeutic Uses of Pitoxil

What Pitoxil Treats: Main Uses and Benefits

Pitoxil is commonly used across therapeutic domains that involve symptoms related to systemic imbalance, particularly conditions associated with acute or disruptive episodes of bacterial origin. Within this context, it is used for managing conditions presenting with systemic or localized discomfort such as community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, acute bacterial sinusitis, complicated skin and soft tissue infections, and complicated intra-abdominal infections. The medication generally helps manage symptoms that interfere with daily functioning like high fever, chills, and functional discomfort caused by a worsening cough or severe localized pain.


This application is relevant when supportive symptom management is appropriate, as it is used for managing symptoms that create noticeable physiological strain. By targeting these conditions, Pitoxil contributes to easing the overall symptom load and may assist with maintaining functional stability during symptomatic periods.


Quick Fact: Relief for Acute Discomfort
Symptom Category Symptoms related to systemic imbalance and heightened physiological activity.
Primary Benefit Provides support that helps ease the overall symptom burden.
Clinical Context Applied in clinical settings that involve acute or unstable symptom patterns.

Regulatory References

  1. Moxifloxacin Tablets Label

Eligibility and Restrictions for Use

Eligibility and Contraindications for Pitoxil (Moxifloxacin)

Pitoxil systemic forms (tablets and injection) are approved for use only in adult patients aged 18 years and older. Its use is governed by strict regulatory rules defining populations who must not take the medicine.


Absolute Contraindications

Pitoxil must not be used in patients with:

  • Known hypersensitivity to moxifloxacin or any other quinolone antibiotic.
  • A history of tendon disorders related to previous quinolone treatment.
  • Specific pre-existing cardiac conditions, including QT interval prolongation, uncorrected hypokalaemia, clinically relevant bradycardia, or certain types of heart failure.
  • Severe hepatic impairment (Child-Pugh Class C) or significantly elevated liver enzymes.
  • A history of Myasthenia Gravis.

Age and Reproductive Eligibility

Population Group Systemic Use Status Restriction Basis
Pediatric Patients (<18 years) Contraindicated Safety and efficacy not established due to potential risk to developing joints.
Pregnancy/Lactation Contraindicated Use is not recommended while pregnant or breastfeeding.

Restricted or Conditional Use

Use requires caution in older patients (over 60) due to a higher risk of tendon rupture, particularly if taking corticosteroids. Caution is also advised for patients with Central Nervous System disorders or ongoing proarrhythmic conditions. No dosage adjustment is required for patients with any degree of renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pitoxil’s interaction profile is defined by specific regulatory prohibitions and mandatory administration requirements. Co-administration with certain medicinal products that prolong the QT interval, such as Class IA and Class III Antiarrhythmics, is strictly contraindicated due to the officially documented risk of an additive effect on cardiac repolarization. This prohibition extends to other substances known to affect the QT interval.

A crucial pharmacokinetic interaction involves products containing multivalent cations, including antacids, sucralfate, and mineral supplements (iron, magnesium, aluminum, zinc). These substances cause decreased absorption of oral Pitoxil. To mitigate this effect, official labeling mandates that oral Pitoxil must be administered at least 4 hours before or 8 hours after these cation-containing products.

The regulatory documents also note pharmacodynamic interactions that result in enhanced risk. Co-administration with Corticosteroids is associated with an increased risk of severe tendon disorders. Combining Pitoxil with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may increase the risks of CNS stimulation. The drug’s metabolism is classified as unlikely to alter the pharmacokinetics of other drugs metabolized by major CYP enzymes. A population-specific restriction notes that co-administration is contraindicated in patients with severe hepatic impairment classified as Child-Pugh C.

Mechanism of Action

Simultaneous Inhibition of Bacterial Topoisomerases

The mechanism of Pitoxil (Moxifloxacin) involves the simultaneous inhibition of two critical bacterial enzymes: DNA gyrase and Topoisomerase IV. The drug binds to and stabilizes the DNA-enzyme cleavage complex, which prevents the re-ligation (resealing) of bacterial DNA strands after they have been cut. This specific, balanced targeting ensures interference with both bacterial DNA replication and chromosome partitioning processes.

Genomic Disruption and the Bactericidal Cascade

By physically preventing the re-ligation of bacterial DNA, the molecular action results in the accumulation of irreversible double-stranded DNA breaks throughout the bacterial genome. This genomic damage halts cellular processes that depend on DNA integrity, such as DNA synthesis and repair. The failure of genomic integrity triggers an active cell death cascade, producing a core bactericidal effect against susceptible target pathogens.

Mechanistic Constraints

The efficacy of the mechanism is constrained by bacterial adaptations. These limitations are typically due to target-based resistance, where mutations in the enzyme genes reduce the binding affinity of Moxifloxacin, or due to the presence of bacterial efflux pumps, which actively transport the drug out of the cell. These factors reduce the effective concentration of the drug at its internal site of action, limiting the intended bactericidal effect.

Dosage and Administration Information

How to Use Pitoxil

Pitoxil is administered via three primary routes, depending on the required therapeutic approach. For systemic use, the drug is available as a 400 mg film-coated tablet for oral ingestion and as a 400 mg in 250 mL solution for intravenous (IV) infusion. An ophthalmic solution is also available for topical use. Sequential therapy, starting with IV administration and switching to the oral tablet, is a documented pattern of use.


The standardized adult systemic dose for all approved indications is 400 mg once daily; this quantity should not be exceeded. The treatment duration is variable and strictly defined by the condition being addressed, ranging from short courses, such as 5 days for certain acute infections, to up to 21 days for complicated skin and soft tissue infections.

Administration Conditions

Oral tablets may be taken with or without food. However, a specific timing constraint applies to ensure proper absorption: the tablet must be ingested at least 4 hours before or 8 hours after products containing multivalent cations, such as antacids or mineral supplements. The IV solution requires slow administration as an infusion over a fixed period of 60 minutes and must not be mixed with other medications in the line. Dosing adjustments are not required for older adults or for patients with any degree of renal impairment, including those on dialysis. Systemic use is generally contraindicated in individuals under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pitoxil


Evidence for Use in Community-Acquired Pneumonia (CAP) and Acute Bronchitis

Research examining Pitoxil (Moxifloxacin) for conditions like Community-Acquired Pneumonia (CAP) has primarily relied on Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time. Researchers focused on outcomes related to systemic or functional imbalance, specifically looking at how long it took for fevers to resolve, the documented clearance of the illness-causing bacteria (microbiological eradication), and the overall clinical success measured shortly after treatment completion.

Studies explored the use of the medicine in both hospitalized and non-hospitalized adults with CAP, including those categorized as mild-to-severe. The findings describe patterns observed in these studies, documenting measurements of clinical outcomes in the observed populations. Research highlights changes measured during the study period, with many trials reporting outcomes that met pre-defined statistical metrics.


Evidence for Use in Sinusitis and Skin/Soft Tissue Infections

Pitoxil was studied for Acute Bacterial Sinusitis (ABS) using Randomized Controlled Trials where it was compared to a placebo (in some cases) or to other standard regimens. These trials monitored physiological strain or stress, specifically looking at measurements of clinical success and patient-reported outcomes describing perceived discomfort. For ABS, follow-up durations were typically short, focusing on changes in symptoms within days of ending the defined course of treatment.

For Complicated Skin and Soft Tissue Infections (cSSTI), the evidence is supported by multiple large-scale Phase III RCTs. These studies were applied in research contexts involving fluctuating or unstable symptoms often associated with surgical wounds, abscesses, or diabetic foot infections. Research examined measurements of clinical success and the documented clearance of pathogens.


Long-Term Studies and Follow-up Durations

Most core studies used for regulatory review of Pitoxil focused on short-term outcomes relevant in trials assessing short-term or episodic symptom patterns, such as the period immediately following the end of antibiotic therapy. The standard follow-up duration for a follow-up assessment is usually scheduled only days after the treatment course is finished.

Therefore, there is limited information for long-term outcomes and durability of response across all indications. Research exploring long-term recurrence rates or how outcomes related to physical discomfort may evolve over several months or years after treatment are not fully established by the primary regulatory evidence.

Key Studies & References

  1. Moxifloxacin Drug Monograph - National Library of Medicine (NIH)
  2. Moxifloxacin Tablets DailyMed Overview - National Library of Medicine (NLM)
  3. Pivotal Trials in Community-Acquired Pneumonia (CAP) supporting Moxifloxacin Registration (Typical search result placeholder)
  4. Studies on Moxifloxacin Use in Complicated Intra-Abdominal Infections (cIAI) (Typical search result placeholder)

Frequently Asked Questions (FAQ)

Common questions about Pitoxil (FAQ)


Q: What is Pitoxil officially approved to treat?

Official documents state that Pitoxil is approved to treat specific types of severe bacterial infections in adults. These typically include conditions like Community-Acquired Pneumonia (CAP), Acute Bacterial Sinusitis, and certain complicated infections of the skin and skin structure. The approved indications specify the types of infections for which this medication may be considered.


Q: Is Pitoxil considered a long-term or short-term medication?

Pitoxil is intended for short-term use. Regulatory documents define the duration of treatment strictly according to the type of infection being treated. These courses typically range from a few days up to a maximum of 21 days, and official information indicates limited data on long-term outcomes.


Q: Can Pitoxil be taken with high blood pressure medicine?

The official prescribing information states that Pitoxil is strictly contraindicated (must not be used) with medications known to prolong the QT interval (a measure of heart rhythm). Individuals taking medication for high blood pressure are advised to verify with a healthcare provider that their specific blood pressure medication does not have this effect, as this could increase the risk of an adverse cardiac event.


Q: Does Pitoxil interact with alcohol consumption?

Official prescribing information does not list a specific drug interaction between Pitoxil and alcohol. However, Pitoxil is associated with certain central nervous system (CNS) effects, such as dizziness or lightheadedness. Because alcohol consumption can increase these side effects, caution is generally warranted.


Q: Are there any known food restrictions while taking Pitoxil?

Pitoxil oral tablets can generally be taken with or without food. The key requirement involves the timing of mineral supplements or certain antacids. Official labeling states that the tablet must be taken at least 4 hours before or 8 hours after any product that contains multivalent cations, such as iron, zinc, calcium, or magnesium.


Q: Is Pitoxil safe for people over the age of 65?

Pitoxil can be used by older adults, and no dosage adjustment is required based on age alone. However, official safety documentation indicates that people over 60 years old face a documented increased risk for severe tendon disorders, particularly if they are also taking corticosteroid medications.


Q: Why does the official documentation list so many precautions for Pitoxil?

The extensive warnings and precautions reflect the drug's regulatory classification as a fluoroquinolone antibiotic. Official documents state that this class of medicine is associated with a risk of serious and potentially disabling side effects, including tendon rupture and nerve damage. The precautions are mandated by regulatory agencies to ensure patients are fully informed of these documented risks.


Q: What were the outcomes of the key clinical trials for Pitoxil?

Studies and official information indicate that the key clinical trials generally met their pre-defined statistical metrics for success. The research showed effectiveness in outcomes such as resolving fevers and documenting the clearance of illness-causing bacteria for the approved infections.


Q: Can Pitoxil interact with common herbal supplements like St. John's Wort?

The official prescribing information specifically details mandatory spacing requirements for mineral supplements to prevent decreased absorption of Pitoxil. While herbal supplements like St. John’s Wort are not typically listed by name in the drug interaction section, official guidance recommends consulting with a healthcare provider regarding any herbal product they are taking.


Q: Why is Pitoxil sometimes linked to [specific organ] issues in safety reports?

Regulatory safety reports officially link Pitoxil to potential adverse effects across several organ systems. These include issues affecting the Musculoskeletal system (tendons), the Cardiac system (heart rhythm), the Nervous System (seizures, nerve damage), and the Hepatobiliary system (liver failure).


Q: Is Pitoxil approved by the European Medicines Agency (EMA)?

Yes, the active ingredient in Pitoxil, Moxifloxacin, has received marketing authorization and is approved for use across the European Union. This approval is based on the review and assessment provided by the European Medicines Agency (EMA).


Q: What if a person has known allergies to inactive ingredients in medicines like Pitoxil?

The official labeling lists hypersensitivity to the active ingredient, Moxifloxacin, or other quinolone antibiotics as an absolute contraindication. Official documents further state that Pitoxil is also contraindicated if a patient has a known allergy to any of the inactive ingredients listed in the full product label.


Q: What is the physical color and shape of the Pitoxil tablet or capsule?

The Pitoxil 400 mg dose is typically manufactured as a film-coated tablet and is often described as having an oval or oblong shape. The color and the imprint found on the tablet's surface can vary depending on whether the medication is the brand-name product or a generic version supplied by different manufacturers.


Q: Is Pitoxil known to cause insomnia or other sleep disturbances?

Yes, Pitoxil is officially associated with adverse reactions affecting the Central Nervous System. Specific events reported in regulatory documents include insomnia (difficulty sleeping) and nightmares.


Q: Does Pitoxil require specific medical monitoring or regular blood tests?

Due to the documented risk of severe liver-related adverse reactions, official guidance advises that monitoring of liver function tests may be considered. This monitoring is particularly advised for patients who may be at a higher risk of liver issues.


Q: Is Pitoxil classified as a controlled substance in the US or other countries?

No, Pitoxil (Moxifloxacin) is classified as a prescription antibiotic. Regulatory bodies like the U.S. Drug Enforcement Administration (DEA) and similar foreign agencies do not classify it as a controlled substance.


Q: Does taking Pitoxil affect a person's ability to drive or operate machinery?

Official patient counseling information recommends caution regarding these activities. Because Pitoxil can cause side effects such as dizziness and lightheadedness, regulatory advice suggests that hazardous activities, such as driving or operating machinery, should be avoided until the individual knows how the medication affects them.


Q: How long does Pitoxil stay in your system after stopping the medication?

The active ingredient (Moxifloxacin) has an elimination half-life of approximately 12 hours. The majority of the active drug is typically eliminated from the body within a few days. However, regulatory documents state that some serious adverse effects, such as tendon disorders, have been reported to occur months after treatment has been completed.


Q: What happens if a patient accidentally takes two doses of Pitoxil close together?

Official documents on overdosage describe the recommended approach, which is focused on providing symptomatic and supportive care. If a patient takes two doses close together or suspects an overdose, immediate medical guidance should be sought.


Q: How does Pitoxil potentially affect fertility?

Official regulatory information indicates that studies in animals have classified the active ingredient in Pitoxil as a potential reproductive hazard. However, the regulatory label notes that human data on fertility is limited or not available at this time.


Q: Can Pitoxil be taken by people with diabetes?

Official safety warnings indicate that patients with diabetes should be aware of a documented risk of dysglycemia, meaning both abnormally high or low blood sugar levels. Official guidance suggests that blood glucose levels may require close monitoring during the course of treatment.


Q: Does Pitoxil cause skin issues or increased sun sensitivity?

Yes, Pitoxil is officially associated with an increased risk of photosensitivity or phototoxicity, meaning the skin can become highly sensitive to sunlight. Regulatory documents advise patients to limit sun exposure, avoid sunlamps, and use sun protection because of the risk of severe sunburn, rash, or blisters.

How should Pitoxil be stored and disposed of?

Storage and Disposal Information

Official regulatory guidelines for Pitoxil (Moxifloxacin) strictly define the required storage and handling conditions to maintain the medicine's stability and efficacy.

Storage Requirement Applicable Formulations
Temperature Store tablets and Intravenous solution at Controlled Room Temperature (20 C to 25 C).
Prohibited Environment Do not freeze the Intravenous or Ophthalmic Solutions to prevent degradation.
Protection Keep the Intravenous Solution in its outer bag to protect from light. Tablets must be protected from moisture.
Child Safety The medicine must be kept out of the sight and reach of children and pets.

For disposal, any unused portion of the single-use Intravenous solution must be discarded. The Ophthalmic Solution should be discarded 4 weeks after first opening. Unused or expired Pitoxil must be disposed of via a drug take-back program or by following the FDA household disposal guidelines (mixing with an undesirable substance and sealing in a container).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pitoxil found in:

A-Z Index: